Treatment of varicose veins with tablets and capsules. Is it possible to cure varicose veins with tablets?

Self-medication for varicose veins is the most popular method of therapy in Russia. The Internet is full of miracle recipes about apple cider vinegar, leeches and other magical technologies, and our fellow citizens willingly believe it. Varicose veins can now be cured inexpensively or even free of charge from certified specialists, but miracle shamans are still very popular. These are probably remnants of the primitive communal system of our ancestors. Only pain can make a person run to the doctor; we will diligently smear various nasty things on uncomplicated varicose veins in the hope that they will someday resolve.

Cure for varicose veins

The vast majority of people, choosing between surgical treatment of any disease (in our case, varicose veins) and possible non-invasive treatment, be it capsules, tablets for varicose veins, gels, ointments, herbs and infusions, will choose the second, especially if from all screens will tell them about their effectiveness and the unnecessaryness of any operations. The amount of information used to intoxicate patients can be judged by the amount of advertising of tablets and creams for varicose veins on all federal channels, where happy girls easily run after lubricating their healthy legs with a miracle cream or taking miracle pills.

What can replace venotonic tablets and capsules?

The only truly effective and efficient treatment for varicose veins at present is vein removal. Innovative interventions have transformed from serious operations to easy and safe outpatient procedures. One or two hours in the clinic and a serious problem with a long history is solved. It’s paradoxical, but modern innovative treatment for varicose veins is not only safe and comfortable, but also much more effective than a classic operation that has been proven for decades.

Modern treatment of varicose veins using sclerotherapy

Do not think that modern drugs are useless. They perfectly perform their functions in the complex treatment of venous pathology. However, treating varicose veins only with tablets and capsules is, at a minimum, not professional.

Do gels, decoctions, tablets and ointments help against varicose veins?

It is much easier and cheaper to take a pill, take infusions or smear inflamed veins, but such effective miracle remedies have not yet been invented, and long-term results testify against this, but self-hypnosis can work a miracle. Whether to throw money away is up to you. Selling medications for varicose veins on the legs has become a profitable business for pharmaceutical companies, since varicose veins are a very common disease.

Remedies for varicose veins are always of interest to suggestible patients, and since the veins do not bother them in the initial stages of the disease, patients are wary of any surgical help. Pharmaceutical companies spend enormous amounts of money to convince the population and even doctors that their pills are the best for varicose veins. The Servier company has been especially successful in this, organizing conferences and “research”, buying famous phlebologists in order to gain their authority to increase sales of its pills.

There are also folk remedies for “getting rid” of varicose veins:

Soda, mumiyo, iodine, peroxide, soap, clay, onion, cabbage, propolis and other remedies for varicose veins in the most miraculous way allow you to get rid of varicose nodes, mesh, as well as kidney and gallstones, tumors and gangrene. Ordinary people believe in this nonsense, not understanding either the causes or consequences of the disease. Thousands of messages on the Internet about magic pills and remedies for varicose veins on the legs are causing confusion in the minds of patients.

Are modern tablets and capsules for the treatment of varicose veins really so ineffective?

The modern pharmaceutical industry offers a large selection of good and high-quality drugs for oral use in the treatment of varicose veins. These agents have significant and proven effects in the treatment of swelling, heaviness, venous pain, cramps and discomfort associated with chronic venous insufficiency.

Modern venotonic - Detralex

But do these drugs treat varicose veins themselves?

A pathologically altered vein is a hollow tube with thinned walls and non-functioning valves. The best treatment, in theory, would be organic restoration of the venous vessel with normalization of the valve apparatus. It’s just that irreversible degenerative changes have already occurred in the venous wall. Today, at this stage of development of modern medicine and pharmacy, there are no effective ways to restore varicose veins, either with the help of interventions or tablets and capsules. Work in this direction is underway, but its effectiveness still leaves much to be desired. Perhaps the dream of restoring a vein destroyed by varicose veins will come true in the coming decades, but we live not in the future, but in the present.

Massage and bath for varicose veins

Massage, unlike many cheap phlebotonics from advertising, is a method of active treatment of varicose veins, helping to prevent edema, relieve swelling itself, fatigue of the lower extremities and reduce overall fatigue of the body.

The Innovative Vascular Center uses all types of modern massage, especially for pathologies of the lymphatic and venous systems. Among the exclusive methods is the technology of lymphatic drainage massage with banding, which very effectively relieves chronic venous insufficiency.

In case of chronic venous insufficiency, massage is used to eliminate venous hypertension in varicose veins and post-thrombotic syndrome. The combination of this technology with banding makes it possible to effectively eliminate all clinical manifestations of the disease.

Therapeutic massage is a very effective means of symptomatic treatment of varicose veins on the legs, but it provides only temporary relief. We use manual lymphatic drainage in patients with severe edema in patients with lymphovenous insufficiency. There is no need to be afraid of “separation of blood clots” with such treatment, but in case of exacerbation it should not be used.

But the bath is a completely different matter: with varicose veins, thrombophlebitis of the lower extremities or post-thrombotic disease, it is very dangerous. Any thermal stress can provoke the formation of blood clots in the deep veins, carried by the bloodstream, with all the ensuing consequences. Dehydration in the bath leads to “thickening” of the blood. Don't expose yourself to unnecessary risks. Varicose veins will not disappear from the bath, but thrombophlebitis may well occur.

When are venotonics prescribed?

Venotonics should be taken from the first signs of vascular problems. Under favorable conditions, that is, when varicose veins are at the zero stage, but unpleasant symptoms such as swelling and heaviness already appear, venoprotectors can prevent the severe consequences of varicose veins and minimize consequences such as thrombosis, thrombophlebitis, and trophic changes.

The earliest stage is the case when it is important to take a comprehensive approach to treatment and “hear” your body.

At later stages, it is recommended to coordinate medications and especially the dosage with your doctor.

Creams and gels for varicose veins

Despite the high effectiveness promoted by sellers and manufacturers, creams and gels do not bring relief from varicose veins and dilated veins do not disappear from them. At the initial stage of venous insufficiency, the doctors conducting the consultation do not strongly object to the use of these supposedly “phlebotropic” drugs, since rubbing them acts like a light massage and promotes venous outflow, and has a calming effect on the skin and walls of blood vessels. In advanced forms of venous insufficiency, these creams and ointments can cause dermatitis and allergization, and are therefore very harmful. Gel "Lioton" and other heparin agents are used in the development of acute thrombophlebitis and help to subside the inflammatory process, but varicose veins do not disappear from them. Shamanic products like “Sophia with leeches” have become very popular thanks to proper advertising with beautiful women’s legs, but they have no relation to medicines, to women, or even to leeches and one can’t expect any sense from them. And also, regardless of the price, rating or well-known name, no drops will bring results, even if absolutely all the reviews talk about the drops as the best and inexpensive medications in the world, phlebotonics, which cure 100% of patients. The best solution would be to contact a good doctor who will prescribe comprehensive minimally invasive or drug treatment and correct your lifestyle.

What are venotonics

Venotonics or they are called phlebotonics, venoprotectors
are medicines that can tone the veins, improve the quality of the walls of blood vessels, properly distribute lymph and establish lymph flow and blood flow, “adjust the quality of details” of our body in order to prevent or get rid of the development of dangerous consequences - blood clots and thrombosis .
Venotonics are presented very widely on pharmacy shelves and each of the drugs has a varying degree of effectiveness, but one common pharmacological effect is increased muscle tone on the walls of blood vessels and an effect on capillary permeability. Taking venotonic drugs is a key point in the successful treatment of varicose veins. While taking the drugs, there is a decrease in unpleasant symptoms in the lower extremities, pain, swelling, and heaviness.

Which brand of tablets for varicose veins is better to choose?

The main indicator of the quality and effectiveness of any product is the manufacturer. Its reputation and operating principles can tell a lot about the product in absentia. Therefore, before starting a detailed review of drugs, get acquainted with pharmacological companies. The best pills for varicose veins were presented by:

• Servier (Detralex) is an international independent pharmaceutical company that was founded in France in 1954. Provides innovative medicines to treat over 100 million people worldwide. This is one of the foreign companies that have localized the production of medicines at their own enterprise in Russia.
• JSC Pharmaceutical Enterprise Obolenskoye (Venarus) - the company was founded in 1994 in Russia on the basis of the State Center for Applied Microbiology. Today, production capacity is increasing - over 600 million tablets and capsules annually. The product portfolio includes 91 names for the treatment of cardiovascular pathologies, gastrointestinal diseases, allergies and other areas.
• Laboratory Innotek International (Phlebodia) - the laboratory is part of the French group. We are talking about a family company founded back in 1913. It specializes in medical and parapharmaceutical products. Since 1995, representative offices have been operating in Russia.
• Novartis (Glivenol) is a group of companies that was founded in Switzerland in 1996 amid the merger of Ciba-Geigy and Sandoz. The group includes 6 brands - Pharma prescription and OTC over-the-counter drugs, Alcon for vision protection, Sandoz biostimulants and generics, Vaccines and Diagnostics test systems and vaccines, Animal Health veterinary products. It ranks second in the world in terms of activity and market share in Europe.
• Boehringer Ingelheim (Antistax) is a family-owned pharmaceutical company that was founded in 1885 in Germany. Today it is one of the top 20 leading global drug production companies. Representative offices operate in 142 countries, including Russia.
• CJSC "Canonpharma Production" (Diosmin) is a company of a new generation of Russian manufacturers, operating since 1998. Complies with modern quality standards and advanced trends in the development of the pharmaceutical market. Effective and safe medications are used to combat a wide range of diseases.
• Balkanpharma-Troyan (Troxevasin) is a Bulgarian company that is part of the international pharmaceutical holding Actavis. Founded in 1998. All manufactured drugs undergo clinical and laboratory tests before going on sale. There are over 40 items on the Russian market.
• Pharma Wernigerode GmbH (Eskuzan) is a German pharmaceutical company that was founded in 1903. Today it is considered one of the most important companies in East Germany. The product portfolio includes all forms of medicines certified according to European standards.
• Nycomed GmbH (Actovegin) is a German company that began its activities in 1874. In Russia, the first representative office was opened in 1993. Offers effective medicines for all areas of medicine. In terms of sales volume, it is among the 30 largest companies in the world.

The best tablets for lamblia

Venous pain - occurrence and treatment

An international group of experts with the participation of the American Venous Forum (AFR), the European Venous Forum (EVF), the International Union of Phlebologists (UIP), and the International Union of Angiologists (IUA) presented a unified terminology characterizing the various manifestations of CVD, recommended for treatment and research work. Thus, it is proposed to distinguish between soreness or pain, a burning sensation, muscle cramps, a feeling of swelling or pulsation, a feeling of heaviness, itching, restless leg syndrome and fatigue [1]. Since all these complaints are not specific, their connection with chronic venous disease is highly likely under the following conditions: direct dependence on the nature of daily activity and the duration of static loads, ambient temperature and hormonal fluctuations in women.

An important sign is the reduction or disappearance of these symptoms after resting or raising the lower extremities above the horizontal level [2]. In addition, a thorough clinical and instrumental examination of the venous system of the lower extremities is necessary.

Specific symptoms of CVD are rarely the subject of epidemiological studies and, as a rule, they are assessed in aggregate. According to various data, the frequency of subjective complaints associated with chronic venous disease occurs in 29-61% of respondents, clearly prevailing in women.

Pain and venous pain: definition and mechanism of development.

As for individual symptoms, in particular venous pain, the range of data is even wider. Thus, Ruckley et al. [3] reported 44% of cases identified by review of medical records. Jawien et al. [4] during a non-specialized examination found venous pain in 75.7% of patients. Langer et al. [5] in a survey of employees at the University of California found pain associated with CVD in 18%. It should be emphasized that pain is often the main reason for patients to see a doctor.

What is venous pain and what is the mechanism of its development? The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.” In other words, pain is usually more than a sensation associated with existing or possible organic damage, since it is accompanied by an emotional component.

There are acute and chronic pain.

• Acute pain is defined as “pain of short duration of onset with an easily identifiable cause.” Acute pain is a warning to the body about the current danger of organic damage or disease.
• Chronic pain was originally defined as “pain that lasts about 6 months or more.” Now, it is pain that “persistently persists beyond the appropriate length of time during which it should normally end.” Previously, it was believed that pain is not a specific physical sensation, and therefore there are no special receptors that perceive only painful stimulation.

That is, the appearance of a feeling of pain can be caused by irritation of any type of nerve endings, if the force of irritation is strong enough. The existence of specialized bolinocyceptor receptors, characterized by a high perception threshold, has now been proven. They are excited only by stimuli of “damaging” intensity.

All nociceptors are free nerve endings that consist only of the terminal branches of the axial cylinder of the sensory neuron, which is why they got their name, and they are located outside the spinal cord stem, but in the dorsal ganglion. The concentration of nociceptors varies throughout the body. They are mainly distributed over the surface of the skin, in ligaments or joint capsules, and are least often found in deeper tissues and organs. Nociceptors recognize mechanical, thermal and chemical stimuli without adapting to them. That is, different individual pain sensitivity thresholds are associated with the emotional and subjective characteristics of the human psyche.

Nociceptive nerves contain small-diameter primary fibers that have sensory endings in various organs and tissues. There are two main classes of nociceptors, Aδ- and C-fibers, which transmit fast and slow pain sensations, respectively. The class of Aδ-myelinated fibers (covered with a thin myelin coating) conduct signals over a distance of 5 to 30 meters per second, serving to transmit rapid pain. This type of pain is felt within one tenth of a second from the moment the painful stimulus occurs. Activation of Aδ-nociceptors occurs as a result of strong mechanical or thermal effects. Slow pain, transmitted through slower, unmyelinated (“naked”) C-fibers that send signals 0.5 to 2 meters per second, is an aching, throbbing, burning pain—such as venous pain. C-nociceptors perceive mechanical, thermal and chemical stimulation.

There are also so-called “sleeping” nociceptors, which are activated during inflammation. Nociceptors have a certain threshold of sensitivity, that is, a certain minimum level of stimuli is required before they lead to the generation of a signal. In some cases, the excitability of pain fibers becomes excessive, exceeding the actual level of exposure to the painful stimulus, which leads to a condition called hypersensitivity to pain - hyperalgesia. Once the threshold is reached, the signal is transmitted along the nerve axon to the dorsal horn of the spinal cord, where the primary processing of sensory information occurs. Then, nociceptive impulses are transmitted through interneurons to the cells of the anterior and lateral horns, causing reflex motor and autonomic reactions. Another part of the impulses excites neurons, the axons of which form ascending pathways. At the level of the hypothalamus and limbic complex, the formation of emotional and behavioral reactions, autonomic and endocrine shifts that accompany pain occurs. The final analysis of incoming nociceptive information is carried out by the cortex of the parietal, frontal and temporal lobes of the brain.

Along with the nociceptive system, there is its antagonist, the antinociceptive system, which suppresses pain impulses. It includes the structures of the cerebral cortex, the diencephalic level, the periventricular and periaqueductal gray matter (rich in enkephalin and opiate neurons), some nuclei of the reticular formation of the brain stem, in which serotonin and norepinephrine act as neurotransmitters. The participation of serotonin and norepinephrine in the functioning of the antinociceptive system explains the reduction of pain caused by a number of drugs (tricyclic antidepressants, etc.) that suppress reuptake at serotonergic and norepinephrine synapses and thereby enhance the descending inhibitory effect on neurons of the dorsal horn of the brain.

Thus, under normal conditions, there is a harmonious relationship between the intensity of the stimulus and the response to it at all levels of organization of the pain system. An imbalance between the nociceptive and antinociceptive systems forms the sensation of pain either due to the activation of the first, or due to the insufficiency of the second, which gives rise to its pathophysiological changes. In terms of temporal characteristics, this relationship can manifest itself in both acute and chronic pain.

The point, however, is not so much in temporal differences as in qualitatively different neurophysiological, psychological and clinical features of the pain syndrome. Thus, acute pain is always a symptom, but chronic pain can essentially become an independent disease. Chronic pain in its pathophysiological basis may have a pathological process in the somatic sphere, primary or secondary dysfunction of the peripheral system, or the central central nervous system, it can also be caused by psychological factors. According to the IASP, pain is a more general concept that includes both objective (associated with nociception) and subjective experiences that are usually accompanied by nociception, but can also occur without any stimuli.

As noted above, nociception (synonyms: nocireception, physiological pain) is activity in the afferent nerve fibers of the peripheral and central nervous system, excited by a variety of stimuli with “damaging” intensity. Nociception is a neurophysiological concept that refers to the perception, conduction and central processing of signals about harmful processes or influences. That is, this is a physiological mechanism for transmitting pain, and it does not affect the description of its emotional component. It is important that the transmission of pain signals in the nociceptive system itself is not equivalent to perceived pain. In other words, patients with CVD can perceive a nociceptive signal in some cases as pain, and in others as burning, pulsation, a feeling of heaviness and other difficult-to-describe sensations.

Pathogenesis of venous pain.

For a long time there was an opinion that peripheral veins do not have pain receptors. Only relatively recently, using electron microscopy, sensory fibers were discovered in the wall of peripheral veins, the cell body of which is located in the dorsal roots of the spinal cord [6]. Sensory fibers pass along the venous wall and are divided into numerous collaterals. Some of them penetrate the adventitia and end in the venous wall between the intima and media. Others penetrate paravasal tissues and end in demyelinated nerve endings that are in close contact with the vessels of the microvasculature. Subendothelial and paravasal nerve endings are nociceptors that transmit afferent signals generated in the venous wall and paravasal tissues.

That is, the pain syndrome that occurs as a result of pathological processes in the venous wall is associated with irritation of nociceptors. Various agents can act as a trigger. In particular, clinical experiments demonstrate that venous pain can be caused by mechanical stimuli such as venipuncture and catheterization, as well as chemical irritation resulting from the administration of cold (<20°C), hyperosmolar, acidic (pH<4) or alkaline solutions (pH> 11) [7].

In addition, inflammation of the venous wall (phlebitis and thrombophlebitis), as well as thrombus formation, can be an inducer of pain syndrome. In some cases, hypoxia stimulates the synthesis of various proinflammatory mediators, which in turn activate subendothelial and paravasal nociceptors. Such substances are called algogens. Venous pain can be studied in vivo. Thus, in a healthy person, a section of the saphenous vein of the forearm is isolated by applying pneumatic cuffs that compress the adductor and efferent segments. Additionally, local anesthesia is performed to block sensory nerve fibers.

Using this model, it was shown that pain occurs when the diameter of the vein is mechanically increased (using a balloon) by more than 3 times. This phenomenon is also clinically confirmed when angioplasty and stenting of the iliac veins are accompanied by severe pain.

Another interesting fact. Venous pain does not occur if the lumen of the vein is expanded using pharmacological agents, for example, by applying adenosine [8]. In other words, dilatation of healthy veins cannot be the cause of pain. This hypothesis is confirmed by the absence of pain in patients with an arteriovenous fistula for hemodialysis.

Numerous epidemiological studies indicate that there is no correlation between the severity of symptoms and the severity of clinical manifestations of CVD. Although, in the Edinburgh epidemiological study in women, a weak connection was established between varicose veins of the main saphenous veins and a number of symptoms (pain, heaviness and itching), nevertheless, 40% of women had severe varicose veins in the complete absence of physical complaints. In contrast, 45% of patients with typical venous pain had no clinical signs of CVD.

Interestingly, in men there was no connection between pain and the severity of varicose veins [9].

What causes venous pain?

Currently, it is associated with an inflammatory reaction caused by phlebostasis. Inflammation of the venous wall not only causes pain, but also acts as a key mechanism leading to varicose transformation with qualitative and quantitative damage to the cellular and tissue components of the venous wall. The trigger for this mechanism may be regional hypoxia caused by capillary stasis. This confirms a significant decrease in the partial oxygen tension in the vessels of the microvasculature after patients with CVD remained in immobile orthostasis for 30 minutes [10].

In addition, it has been proven that it is hypoxia in the microvasculature that causes activation of endothelial cells, which is manifested by an increase in the concentration of calcium in their cytoplasm, which in turn leads to an increase in the activity of phospholipase A2. Activation of phospholipase A2 is one of the key mechanisms for the synthesis of inflammatory mediators such as bradykinin, prostaglandins E2 and D2, platelet activating factor (PAF) and leukotriene B4. PAF increases local serotonin and histamine activity, causing increased adhesion of neutrophils to the venous endothelium. This process subsequently leads to the infiltration of the venous wall by active neutrophils and their stimulation of the synthesis of leukotriene B4.

Evidence of damage to the venous wall as a result of the inflammatory response, in which neutrophils and endothelial cells are the main participants, has been accumulating over the past 5 years. The presence of neutrophils, monocytes, activated T-lymphocytes, accumulation of macrophages and mast cells, expression of cell adhesion molecules on the surface of leukocytes and endothelial cells (LFA-1, VLA-4, ELAM-1, ICAM-1, VCAM-1), synthesis of cytokines ( IL-1 beta, IL-6, TNF alpha) and prothrombotic factors (von Willebrandt) serve as objective criteria for the inflammatory process in the vein wall.

Many proinflammatory mediators synthesized as a result of hypoxia can act as algogens that activate venous and paravasal nociceptors. In particular, intravenous or paravasal administration of bradykin causes pain in healthy people. A number of studies show that the algogenic effect of bradykinin depends on the synthesis of NO by endothelial and smooth muscle cells of the venous wall, followed by activation of cGMP synthesis [11]. The pain effect of bradykinin is potentiated by prostaglandin E2, which, although itself not an algogen, increases the sensitivity of nociceptors.

In other words, the generation of venous pain occurs as a result of self-accelerating cascade reactions, with the participation of various substances (a kind of “inflammatory mixture”), which not only activate nociceptors, but also disrupt vascular permeability, leading to plasma extravasation with the development of transmural and tissue edema. Over time, this process causes damage to the venous wall with disintegration of its structure and loss of normal elastic properties.

Indirect confirmation of the presented hypothesis is the increase in NO levels and markers of endothelial dysfunction as CVD progresses. Here, it is logical to assume that the severity of inflammation in the vein wall, and, consequently, the level of inflammatory markers will directly correlate with the intensity of the pain syndrome and the degree of varicose transformation.

Meanwhile, this hypothesis was not confirmed in a clinical study, when blood samples were taken from a vein in the dorsum of the foot from 132 patients (C2-C5 according to CEAP) and the level of 12 inflammatory markers was correlated with the intensity of pain assessed on a visual analogue scale [12] . Moreover, it turned out that the pain syndrome does not correlate with the severity of varicose transformation of the saphenous veins.

Thus, there must be some pathophysiological mechanism that induces pain. This can be regional hypoxia, which is provoked by a variety of situations. Indeed, venous pain and other nociceptive disorders usually appear at the end of the working day, after prolonged periods of sitting or standing, as well as during certain phases of the menstrual cycle. Moreover, all these symptoms can occur, not only against the background of visible pathomorphological changes in the venous system in patients with CVD.

In other words, a cascade of chemical reactions that activate venous and paravasal nociceptors is formed long before the pathological remodeling of the venous wall. This position is confirmed by the higher frequency of subjective complaints, including venous pain and heaviness in the legs in patients in the absence of both varicose veins and pathological venovenous reflux. Thus, venous pain and varicose transformation of the venous wall are based on similar biochemical and molecular cellular mechanisms, in particular inflammation. At the same time, the time period required for the development of varicose transformation of peripheral veins, as a rule, is significantly longer in comparison with pain and other nociceptive manifestations in patients with CVD.

How can we explain the significant reduction in pain and other symptoms in the later stages of CVD?

Apparently, this is due to damage to subendothelial and paravasal nociceptors. Damage to sensory nerve endings reflects peripheral neuropathy associated with venous microangiopathy and increased endoneurial pressure. This is confirmed by the fact that in the later stages of CVD the threshold for tactile, vibration and temperature sensitivity increases significantly, which can be explained by the loss of sensory axons. Interestingly, the sensory threshold increases significantly in patients with C5 compared with C2 class CVD [13].

Thus, the decrease in pain in the later stages of the disease can be explained by a decrease in the number of nociceptors.

Pain syndrome is also determined by other components, depending on the individual characteristics of the patient. Such options would include both the reactivity of cellular components (endothelial cells, neutrophils, venous and paravasal nociceptors) and the mechanisms of integration of nociceptive stimuli in the brain. In particular, the amount of different prostaglandins synthesized by endothelial cells is determined by at least 10 individual factors. Similarly, neutrophil activity depends on age and previous sensitivity to various inflammatory signals. In addition, the density of venous and paravenous innervation, as well as the density of ion nociceptive channels that transform a chemical signal into a nerve impulse, has individual characteristics. The resulting chain of these algogenic processes is modulation in the brain, which in turn depends on the effect of endogenous opioids, which vary and depend on genetic factors. An example is the genotype of the enzyme catechol-0-methyl-transferase, which determines the amount of endogenous opioids during a pain impulse and significantly influences pain sensitivity in healthy people [14].

The search for a correlation between the severity of venous pain and other subjective symptoms with the nature of changes in the peripheral venous bed and other factors in patients with CVD is hampered by both the lack of special validated questionnaires and sensitive instrumental methods. In addition, the presence of diverse and poorly controlled endogenous and exogenous factors hinders the study of the exact mechanisms of venous pain and other symptoms of CVD. That is why, the main searches are carried out in experimental studies of the interaction between inflammatory mediators and nociceptors [15,16].

Treatment of venous pain and other symptoms of chronic venous diseases.

Treatment of venous pain and other nociceptive symptoms associated with CVD involves a preliminary objective assessment of not only the state of the venous system of the lower extremities, but also the general clinical status, including psychological, behavioral, and, if necessary, neurophysiological characteristics. In some cases, it is advisable to involve specialized specialists: neurologists and psychoneurologists.

In general, the treatment of symptoms and syndromes that occur with chronic venous disease fits into the general concept of pain syndrome therapy, which includes:

• Elimination of the source of pain and restoration of damaged tissues;
• Impact on peripheral components of pain: elimination of inflammation and swelling, suppression of the synthesis of prostaglandins and other algogens;
• Inhibition of pain impulses along peripheral nerves;
• Impact on processes occurring in the dorsal horns of the spinal cord;
• Impact on the psychological (and at the same time neurochemical) components of pain using pharmacological drugs and psychotherapeutic methods.

The most important component of the pathogenetic treatment of venous pain is compression therapy using bandages or medical knitwear. Its use makes it possible to improve venous blood circulation and microcirculation in the shortest possible time, thereby reducing the degree of excitation of intravenous and paravasal nociceptors.

The prescription of phlebotropic drugs (synonyms: venotonics, phleboprotectors) deserves special discussion. Currently, they are considered as a first-line treatment for the treatment of symptomatic forms of CVD [17,18]. As already discussed above, the most striking nociceptive symptoms appear in the earliest stages of the formation of CVD, when there are no significant disturbances in the venous circulation, and the pathological process affects mainly the microvasculature. Under these conditions, the main task is to suppress the leukocyte-endothelial reaction and its consequences in the form of uncontrolled synthesis of various biologically active substances, many of which act as algogens [19,20].

How do phlebotropic drugs affect venous pain?

RELIEF was one of the first studies where, on a large clinical material (3132 patients, C0S-C4) using a specialized questionnaire (CIVIQ) and a visual analogue scale (VAS), a significant reduction in pain and other symptoms caused by both organic (valvular insufficiency) and ), and functional (phlebopathy) damage to the venous system of the lower extremities [21].

Of interest are the results of a recent double-blind, placebo-controlled study of 592 patients (C3-C4A) with superficial (34%), deep or perforating vein reflux (66%) who had venous pain initially assessed as greater than 4 cm YOUR. Patients in the main group received 2 tablets of Detralex per day, while in the control group - 2 tablets of placebo. Control endpoints were a decrease in pain by at least 3 cm on the VAS scale and an increase in quality of life by at least 20 points on the CIVIQ scale. These results were achieved in 24.6% of patients receiving Detralex and 14.8% of the placebo group (RR=1.67) [22].

What is the optimal duration of pharmacotherapy for pain and other symptoms caused by CVD? To some extent, the answer to this question is provided by a multicenter study by Guillot et al., who recorded a significant decrease in CVD symptoms assessed by a doctor using VAS (values ​​from 0 to 5) every 2 months. All patients took 2 Detralex tablets daily for 12 months. According to the results of the study, a maximum decrease (by approximately 50%) in the severity of CVD symptoms was noted in the first two months. Subsequently, this trend, although less pronounced, persisted, which was noted at each clinical examination [23].

In a high-profile meta-analysis of 5 randomized trials examining the treatment of patients with C6 (open trophic ulcers), Coleridge-Smith et al. [24] showed that the inclusion of Detralex not only promotes faster closure of venous trophic ulcers with an area of ​​up to 10 cm2, but also significantly reduces the severity of pain.

In the context of the prevention of pain in patients with CVD, two more works deserve attention, devoted to the analysis of the features of the perioperative period in patients with C2 who received Detralex. Thus, Veverkova et al. [25] demonstrated a significant reduction in the amount of analgesics required for postoperative pain relief after safenectomy in patients receiving Detralex. Similar data were obtained during the Russian multicenter study DEFANCE [26,27].

Concluding this review, it should be noted that many controversial issues remain regarding both the pathogenesis of chronic venous diseases and methods of their treatment. Only a number of key provisions are beyond doubt:

• Treatment of CVD must begin as early as possible, even when there are no signs of organic damage to the venous bed, but symptoms characteristic of this disease are present.
• It is advisable to use a set of measures, including both conservative methods (normalization of lifestyle, compression, pharmacotherapy, etc.) and surgical interventions, the volume of which should be exactly commensurate with the nature and extent of damage to the venous bed.
• Like any chronic disease, venous insufficiency, regardless of its genesis, tends to recur. That is why all patients with CVD, regardless of whether they have been operated on or not, require lifelong monitoring with, if necessary, therapeutic and preventive measures.

Literature:

1. Eklof Bo, Perrin M., Konstantinos T. Delis et al. Update terminology of chronic venous disorders: The VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009; 49:498-501.
2. Labropoulos N., Stansby G. Venous and Lymphatic Diseases. Taylor & Francis.2006; 559.
3. Ruckley CV, Fowkes FGR, Bradbury AW Venous Disease. Epidemiology, Management and Delivery of Care. Springer.1999; 278.
4. Jawien A., Grzela T., Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40095 patients. Phlebology. 2003; 81: 110-122.
5. Langer RD, Ho E, Deneberg JO, et al. Relationship between symptoms and venous disease. Arch Int Med 2005;165:1420-1424.
6. Arndt JO, Klement W. Pain evoked by polymodal stimulation of hand veins in humans. J Physiol 1991;440:467.
7. Klement W., Arndt JO Pain but no sensation temperature are evoked by termal stimulation of cutaneous veins in man. Neurosci Lett.1991;123:119-122.
8. Klement W., Arndt JO Adenosine does not evoke pain from venous and paravascular nociceptors in the human. Cardivasc Res 1992;26:186-189.
9. Bradbury A., Evans C., Allan P., et al. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ.1999;318:353-356.
10. Badier-Commandier C., Jacob MP, Michel JB Le remodelage variqueux. Medecine Therapeutique.2006;6:718-723.
11. Danziger N. Pathophysiology of pain in venous disease. Phlebolymphology.2008; 15: 107-114
12. Howlader MH, Smith PD Symptoms of chronic venous disease and association with systemic inflammatory markers. J Vasc Surg 2003;38:950-954.
13. Padberg FT Jr., Maniker AH, Carmel G., et al. Sensory Impairment: a feature of chronic venous insufficiency. J Vasc Surg 1999;30:836-842.
14. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT vall58met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science.2003;299:1240-1243.
15. Ramelet AA, Boisseau MR, Allegra C.et all. Veno-active drugs in the management of chronic venous disease. An international consensus statement: Current medical position, prospective views and final resolution. Clinical Hemorheology and Microcirculation. 2005; 33: 309-319
16. Bergan J., Scmid-Schonbein G., Coleridge-Smith Ph., et al. Chronic Venous Disease, N Engl J Med. 2006; 355:488-498
17. Schmid-Schonbein GW, Granger DN Molecular Basis for Microcirculatory Disorders. Springer. 2003; 640
18. Bergan J., Shortell C. Venous Ulcers. Elsevier. 2007; 341
19. Nicolaides AN, Allegra C., Bergan J. et all. Management of Chronic Venous Disorders of the Lower Limbs Guidelines According to Scientific Evidence. International Angiology. 2008; 27: 1-59
20. Ramelet A.A., Perrin M., Kern P., Bounameaux H. Phlebology, 5th edition, Elsevier Masson. 2008: 565
21. Jantet G. RELIEF Study Group. Chronic Venous Insufficiency: Worldwide Results of the RELIEF Study. Angiology. 2002; 53: 245-256
22. Pitsch F. Assessment of treatment efficacy on venous symptoms: the example of Detralex. Phlebolymphology.2008; 15: 137-142.
23. Guillot B., Guilhou JJ, de Champvallins M., et al. A long term treatment with a venotropic drug: results on efficacy and safety on Daflon 500 mg in chronic venous insufficiency. Int Angiol. 1989; 8: s67-s71.
24. Colerige-Smith P., Lok C., Ramelet A.A. Venous leg ulcer: meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005; 30: 198-208
25. Veverkova L., Jedika V., Wechsler J., et al. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg on postoperative symptoms. Phlebolymphology.2006;13: 195-201
26. Savelyev V.S., Pokrovsky A.V., Kirienko A.I., et al. Surgical intervention for varicose veins “under the cover” of micronized diosmin. Angiology and vascular surgery.-2007; 13:47-55
27. Saveljev V., Pokrovsky A., Kirienko A., et all. Striping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology. 2008; 15:43-51

Pain syndrome after treatment

Pain syndrome after surgery is associated with the degree of trauma.
If sclerotherapy of the veins of the lower extremities was performed, the pain is slightly stronger than the pain from an injection. If EVLO was chosen as the main treatment method, conventional painkillers can be used to eliminate pain. In both cases, compression hosiery is used, which simultaneously facilitates the correct completion of treatment and relieves pain. When performing a classic phlebectomy, the pain can be significant, so the whole range of means is used, starting from painkillers and massage, and ending with the continuous wearing of compression stockings around the clock. After treatment, we monitor the patients’ condition to prevent any complications, and before it begins, we conduct a full consultation and answer your questions. We invite you to get answers by scheduling your first consultation!

Questions from patients about the use of venotonic drugs

Ninel from Moscow is interested: do you recommend tablets for the treatment of varicose veins?

Dear Ninel! Specialists at the Moscow City Phlebology Center use tablet forms of oral phlebotonic drugs in the complex treatment of varicose veins.

Ekaterina from Moscow asks: is it possible to cure varicose veins with pills?

Dear Ekaterina! It is impossible to cure varicose veins with pills alone. Modern treatment of venous pathology involves the use of venotonic drugs in the complex treatment of varicose veins, but not monotherapy with tablets.

Lyudmila from Moscow is interested in: what medications for varicose veins are best to use today?

Dear Lyudmila! In modern phlebological practice, the most proven effect in the treatment of venous pathology is possessed by drugs of the diosmin group and micronized purified flavonoid fraction.

Varvara from Moscow asks: is it possible to take pills for varicose veins after vein removal surgery?

Dear Varvara! The use of modern oral drugs of the venotonic group has a positive effect on the course of the postoperative period, in the absence of contraindications. Therefore, such therapy is recommended.

WHAT IS THE EFFECT OF PAIN RELIEF FOR VARICOSE?

Some drugs only relieve pain; diclofenac and indomethacin, in addition to pain relief, remove inflammation and improve blood flow. Aspirin is used in medical practice; it improves blood rheology and promotes its movement through the veins.

Analgin and aspirin demonstrate an analgesic effect; menovazine is used for local rubbing; it not only locally reduces pain, but also improves blood circulation. Phlebotonics are used to reduce swelling and a feeling of heaviness.

Which tablets for varicose veins are best to buy?

All 9 nominees in the rating demonstrate high quality, positive results, and a large percentage of positive reviews from customers. This raises the question, what pills to take for varicose veins and what is better to buy from the list presented? Experts insist on consulting a doctor, and also summarize the following review results:

• Detralex - good value for money, quality and effectiveness;
• Troxevasin is the most purchased drug, increasing local immunity;
• Aescusan is an effective drug for the prevention of thrombosis;
• Phlebodia – high safety, the best choice for pregnant women;
• Actovegin is an antihypoxant with metabolic properties;
• Glivenol is the most effective tablet for any stage of varicose veins.

It is possible to select effective medications against varicose veins only after examining the patient in a clinical setting. The individual characteristics of the body, concomitant disorders, existing symptoms, and age are taken into account. Self-medication with such a diagnosis is unacceptable, as it leads to serious complications.